Through an integrated analysis combining network pharmacology and machine learning, we identified PTGS2 and MMP9 as key targets of Chrysanthemum in the treatment of AD, along with critical pathways such as the NF-κB signaling pathway and IL-17 signaling pathway. This evidence concerns the gene IL17A and Alzheimer disease.